Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke

Neurochemical Research

Volumn 38, Issue 12, 2013, Pages 2668-2677

  Ishrat, Tauheed ^a,b   Pillai, Bindu ^a,b   Ergul, Adviye ^a,b,c   Hafez, Sherif ^a,b   Fagan, Susan C ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Candesartan; Embolic stroke; Hemorrhage; Matrix metalloproteinases; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; CANDESARTAN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CONTINUOUS INFUSION; CONTROLLED STUDY; EMBOLIC STROKE; ENZYME ACTIVATION; ENZYME ACTIVITY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT RESPONSE;

RATTUS; RATTUS NORVEGICUS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BLOTTING, WESTERN; EMBOLISM; ENZYME ACTIVATION; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, WISTAR; STROKE; TETRAZOLES; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890309262     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1185-y     Document Type: Article

References (53)

1. Goldstein LB (2007) Acute ischemic stroke treatment in 2007. Circulation 116:1504-1514
2. Ishrat T, Soliman S, Guan W, Saler M, Fagan SC (2012) Vascular protection to increase the safety of tissue plasminogen activator for stroke. Curr Pharm Des 18:3677-3684
3. Fagan SC, Hess DC, Machado LS, Hohnadel EJ, Pollock DM, Ergul A (2005) Tactics for vascular protection after acute ischemic stroke. Pharmacotherapy 25:387-395
4. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jahnig P, Herrmann M, Knauth M, Bahr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C (2009) Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke J Cereb Circ 40:e647-e656
5. Jia L, Chopp M, Zhang L, Lu M, Zhang Z (2010) Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke. Stroke J Cereb Circ 41:2071-2076
6. Zechariah A, ElAli A, Hermann DM (2010) Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke J Cereb Circ 41:1008-1012
7. Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, Lo EH (2003) Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9:1313-1317
8. Pfefferkorn T, Rosenberg GA (2003) Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke J Cereb Circ 34:2025-2030
9. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke J Cereb Circ 32:1759-1766
10. Cunningham LA, Wetzel M, Rosenberg GA (2005) Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50:329-339
11. Romanic AM, Madri JA (1994) Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol 4:145-156
12. Grossetete M, Rosenberg GA (2008) Matrix metalloproteinase inhibition facilitates cell death in intracerebral hemorrhage in mouse. J cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 28:752-763
13. Power C, Henry S, Del Bigio MR, Larsen PH, Corbett D, Imai Y, Yong VW, Peeling J (2003) Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 53:731-742
14. Wells JE, Biernaskie J, Szymanska A, Larsen PH, Yong VW, Corbett D (2005) Matrix metalloproteinase (MMP)-12 expression has a negative impact on sensorimotor function following intracerebral haemorrhage in mice. Eur J Neurosci 21:187-196
15. Alvarez-Sabin J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribo M, Santamarina E, Quintana M, Monasterio J, Montaner J (2004) Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke J cerebral circulation 35:1316-1322
16. Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen HR (2007) Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 5:1732-1739
17. Nishimura Y, Ito T, Saavedra JM (2000) Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke J Cereb Circ 31:2478-2486
18. Awad AS (2011) Effect of combined treatment with curcumin and candesartan on ischemic brain damage in mice. J Stroke Cerebrovasc Dis 20:541-548
19. Fu H, Hosomi N, Pelisch N, Nakano D, Liu G, Ueno M, Miki T, Masugata H, Sueda Y, Itano T, Matsumoto M, Nishiyama A, Kohno M (2011) Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. J Hypertens 29:2210-2219
20. Guan W, Kozak A, El-Remessy AB, Johnson MH, Pillai BA, Fagan SC (2011) Acute treatment with candesartan reduces early injury after permanent middle cerebral artery occlusion. Transl Stroke Res 2:179-185
21. Guan W, Somanath PR, Kozak A, Goc A, El-Remessy AB, Ergul A, Johnson MH, Alhusban A, Soliman S, Fagan SC (2011) Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. PLoS ONE 6:e24551
22. Kozak A, Ergul A, El-Remessy AB, Johnson MH, Machado LS, Elewa HF, Abdelsaid M, Wiley DC, Fagan SC (2009) Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke J Cereb Circ 40:1870-1876
23. Elewa HF, Kozak A, Johnson MH, Ergul A, Fagan SC (2007) Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. J Hypertens 25:855-859
24. Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, Ergul A, Hess DC (2006) Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens 24:535-539
25. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR (1997) A rat model of focal embolic cerebral ischemia. Brain Res 766:83-92
26. Meng W, Wang X, Asahi M, Kano T, Asahi K, Ackerman RH, Lo EH (1999) Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 19:1316-1321
27. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH (2008) Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke J Cereb Circ 39:3372-3377
28. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H (1986) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke J Cereb Circ 17:472-476
29. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, Fernandez-Cadenas I, Ribo M, Molina CA, Lo EH, Montaner J (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke J Cereb Circ 37:1399-1406
30. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC (1998) Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke J Cereb Circ 29:1020-1030
31. Gurney KJ, Estrada EY, Rosenberg GA (2006) Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 23:87-96
32. Suzuki Y, Nagai N, Yamakawa K, Kawakami J, Lijnen HR, Umemura K (2009) Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. Blood 114:3352-3358
33. Liu H, Kitazato KT, Uno M, Yagi K, Kanematsu Y, Tamura T, Tada Y, Kinouchi T, Nagahiro S (2008) Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in vivo and in vitro studies. J Hypertens 26:1435-1445
34. Engelhorn T, Doerfler A, Heusch G, Schulz R (2006) Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats. Neurosci Lett 406:92-96
35. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH (2000) Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab Off J Int Soc Cerebral Blood Flow Metab 20:1681-1689
36. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-2392
37. Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:21491-21494
38. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi A, Miller K, Gearing A (2001) Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893:104-112
39. Kelly-Cobbs AI, Prakash R, Li W, Pillai B, Hafez S, Coucha M, Johnson MH, Ogbi SN, Fagan SC, Ergul A (2013) Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes. Am J Physiol Heart Circ Physiol 304:H806-H815
40. Jian Liu K, Rosenberg GA (2005) Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 39:71-80
41. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, Schulz R (2004) The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab Off J Int Soc Cerebral Blood Flow Metab 24:467-474
42. Sutherland BA, Papadakis M, Chen RL, Buchan AM (2011) Cerebral blood flow alteration in neuroprotection following cerebral ischaemia. J Physiol 589:4105-4114
43. Suzuki Y (2010) Role of tissue-type plasminogen activator in ischemic stroke. J Pharmacol Sci 113:203-207
44. Hallenbeck JM (2002) The many faces of tumor necrosis factor in stroke. Nat Med 8:1363-1368
45. Shohami E, Ginis I, Hallenbeck JM (1999) Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 10:119-130
46. Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz MA (1996) Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 16:981-987
47. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC (1998) Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 101:731-736
48. Yamakawa H, Jezova M, Ando H, Saavedra JM (2003) Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 23:371-380
49. Sanz-Rosa D, Oubina MP, Cediel E, de Las Heras N, Vegazo O, Jimenez J, Lahera V, Cachofeiro V (2005) Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol 288:H111-H115
50. Sandset EC, Bath PM, Boysen G, Jatuzis D, Korv J, Luders S, Murray GD, Richter PS, Roine RO, Terent A, Thijs V, Berge E (2011) The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377:741-750
51. Alhusban A, Kozak A, Ergul A, Fagan SC (2013) AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. J Pharmacol Exp Ther 344:348-359
52. Zhou J, Pavel J, Macova M, Yu ZX, Imboden H, Ge L, Nishioku T, Dou J, Delgiacco E, Saavedra JM (2006) AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke J Cereb Circ 37:1271-1276
53. Steckelings UM, Paulis L, Namsolleck P, Unger T (2012) AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 21:142-146